Clinical trial BOT112-02
Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Highlight Therapeutics S.L. |
| EudraCT Identifier | 2019-004624-38 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04508140 |
| Inclusion criteria | unresectable liver metastases |
| Last update |